Literature DB >> 27313676

Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells.

Xiao Chen1, Dong-Dong Wang2, Tong Wei2, Su-Mei He2, Guan-Ying Zhang2, Qun-Li Wei2.   

Abstract

Diabetic nephropathy (DN) exhibits a deteriorating course that may lead to end-stage renal failure. Astragalosides have been clinically tested for the treatment of DN, but the mechanism is unclear at present. In this study, the effects of astragalosides were investigated on high glucose-induced proliferation and expression of transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), type IV collagen (colIV) and fibronectin (FN) in glomerular mesangial cells (MCs). Cell proliferation was determined by 5-bromo-2'-deoxyuridine assay, and the expression of TGF-β1, CTGF, colIV and FN mRNA and proteins in MCs was detected by reverse transcription-polymerase chain reaction and ELISA assay, respectively. The results showed that high glucose clearly induced the proliferation of MCs and increased the expression of TGF-β1, CTGF, colIV and FN. Treatment with 50, 100, 200 µg/ml astragalosides inhibited cell proliferation and the expression of TGF-β1, CTGF, colIV and FN induced by high glucose. Thus, it is concluded that astragalosides inhibit the increased cell proliferation and expression of major extracellular matrix proteins that are induced by high glucose, indicating their value for the prophylaxis and therapy of DN.

Entities:  

Keywords:  astragalosides; cell proliferation; diabetic nephropathy; extracellular matrix; mesangial cells

Year:  2016        PMID: 27313676      PMCID: PMC4888024          DOI: 10.3892/etm.2016.3194

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

Review 1.  Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.

Authors:  O V Sakharova; M W Taal; B M Brenner
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-11       Impact factor: 2.894

Review 2.  Clinical practice. Nephropathy in patients with type 2 diabetes.

Authors:  Giuseppe Remuzzi; Arrigo Schieppati; Piero Ruggenenti
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 3.  Transforming growth factor-beta/connective tissue growth factor axis in the kidney.

Authors:  Weier Qi; Xinming Chen; Philip Poronnik; Carol A Pollock
Journal:  Int J Biochem Cell Biol       Date:  2007-01-20       Impact factor: 5.085

4.  Role of oxidative stress in advanced glycation end product-induced mesangial cell activation.

Authors:  Mark A Lal; Hjalmar Brismar; Ann-Christine Eklöf; Anita Aperia
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

5.  Pathologic classification of diabetic nephropathy.

Authors:  Thijs W Cohen Tervaert; Antien L Mooyaart; Kerstin Amann; Arthur H Cohen; H Terence Cook; Cinthia B Drachenberg; Franco Ferrario; Agnes B Fogo; Mark Haas; Emile de Heer; Kensuke Joh; Laure H Noël; Jai Radhakrishnan; Surya V Seshan; Ingeborg M Bajema; Jan A Bruijn
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

Review 6.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

7.  Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse.

Authors:  K Sharma; F N Ziyadeh
Journal:  Am J Physiol       Date:  1994-12

8.  Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.

Authors:  Mausumee Guha; Zhong-Gao Xu; David Tung; Linda Lanting; Rama Natarajan
Journal:  FASEB J       Date:  2007-06-06       Impact factor: 5.191

9.  Astragalus injection protects cerebral ischemic injury by inhibiting neuronal apoptosis and the expression of JNK3 after cerebral ischemia reperfusion in rats.

Authors:  Guangyi Liu; Jinming Song; Yunliang Guo; Tingting Wang; Zhen Zhou
Journal:  Behav Brain Funct       Date:  2013-10-01       Impact factor: 3.759

10.  Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling.

Authors:  Ting Ting Zhao; Hao Jun Zhang; Xiao Guang Lu; Xiao Ru Huang; Wei Ku Zhang; Hua Wang; Hui Yao Lan; Ping Li
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more
  9 in total

Review 1.  Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.

Authors:  Zubair Ilyas; Joumana T Chaiban; Armand Krikorian
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

2.  Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats.

Authors:  Dong Han
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

3.  Maresin 1 Mitigates High Glucose-Induced Mouse Glomerular Mesangial Cell Injury by Inhibiting Inflammation and Fibrosis.

Authors:  Shi Tang; Chenlin Gao; Yang Long; Wei Huang; Jiao Chen; Fang Fan; Chunxia Jiang; Yong Xu
Journal:  Mediators Inflamm       Date:  2017-01-15       Impact factor: 4.711

4.  Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice.

Authors:  Xiaolei Wang; Yanbin Gao; Nianxiu Tian; Dawei Zou; Yimin Shi; Nan Zhang
Journal:  Drug Des Devel Ther       Date:  2018-08-06       Impact factor: 4.162

5.  Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis.

Authors:  Hui Jiang; Fu-Rong Wu; Jian Liu; Xiu-Juan Qin; Nan-Nan Jiang; Wei-Ping Li
Journal:  Int J Mol Med       Date:  2019-07-22       Impact factor: 4.101

6.  Qishen Yiqi Dripping Pill Protects Diabetic Nephropathy by Inhibiting the PI3K-AKT Signaling Pathways in Rats.

Authors:  Shaohua Li; Guangbiao Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-17       Impact factor: 2.650

7.  Long read reference genome-free reconstruction of a full-length transcriptome from Astragalus membranaceus reveals transcript variants involved in bioactive compound biosynthesis.

Authors:  Jun Li; Yuka Harata-Lee; Matthew D Denton; Qianjin Feng; Judith R Rathjen; Zhipeng Qu; David L Adelson
Journal:  Cell Discov       Date:  2017-08-29       Impact factor: 10.849

8.  Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.

Authors:  Xiaolei Wang; Yanbin Gao; Nianxiu Tian; Zhiyao Zhu; Tao Wang; Jiayi Xu; Bingjie Wu; Nan Zhang
Journal:  Drug Des Devel Ther       Date:  2018-09-12       Impact factor: 4.162

9.  Astragaloside IV ameliorates high glucose‑induced renal tubular epithelial‑mesenchymal transition by blocking mTORC1/p70S6K signaling in HK‑2 cells.

Authors:  Xiao Chen; Yang Yang; Chenxu Liu; Zhigao Chen; Dongdong Wang
Journal:  Int J Mol Med       Date:  2018-11-26       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.